1-Methyl-1-aza-cycloundecan | 19719-82-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Methyl-1-aza-cycloundecan
• 英文别名: 1-methyl-azacycloundecane
• CAS: 19719-82-5
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: HYSIHRLJXQKIEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Methyl-1-aza-cycloundecan 以 苯 为溶剂， 生成 癸-9-烯基二甲基胺
  参考文献：
  名称：

  Structural and mechanistic effects on the rates of ring-opening reactions in the 5-16-membered-ring region

  摘要：

  DOI：

  10.1021/jo01308a002
• 作为产物：
  描述：

  sodium methylate 、 1,1-dimethyl-azoniacycloundecane; iodide 以 甲醇 为溶剂， 生成 1-Methyl-1-aza-cycloundecan 、 癸-9-烯基二甲基胺 、 (10-Methoxy-decyl)-dimethyl-amine
  参考文献：
  名称：

  Structural and mechanistic effects on the rates of ring-opening reactions in the 5-16-membered-ring region

  摘要：

  DOI：

  10.1021/jo01308a002

文献信息

• [EN] BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：REMPEX PHARMACEUTICALS INC

  公开号：WO2016149393A1

  公开（公告）日：2016-09-22

  Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

  本文揭示了抗微生物化合物组合物、药物组合物及其使用和制备。一些实施例涉及硼酸衍生物及其作为治疗剂的使用。
• [EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125534A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及公式（I）的药物制剂，用于治疗和/或预防哺乳动物，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK - 也称为MAP3K14）抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125530A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及一种公式（I）的药物制剂，用于治疗和/或预防哺乳动物中的疾病，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK，也称为MAP3K14）的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] OXAMAZIN ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES À BASE D'OXAMAZINE
  申请人：REMPEX PHARMACEUTICALS INC

  公开号：WO2014164526A1

  公开（公告）日：2014-10-09

  Disclosed herein are oxamazin monobactam compounds and their use as antibiotics resistant to degradation by β-lactamases. Also disclosed are pharmaceutical compositions containing the compounds and methods of synthesis.

  本文披露了氧氨噁唑单环内酰胺化合物及其作为抗β-内酰胺酶降解的抗生素的用途。同时还披露了含有这些化合物的药物组合物和合成方法。
• Urea-Oxaziridines
  申请人：The Regents of the University of California

  公开号：US20210155600A1

  公开（公告）日：2021-05-27

  Chemoselective conjugation is achieved through redox reactivity by reacting an N-transfer oxidant with a thioether substrate in a redox reaction in an aqueous environment to form a conjugation product. In embodiments, Redox-Activated Chemical Tagging (ReACT) strategies for methionine-based protein functionalization. Oxaziridine (Ox) compounds serve as oxidant-mediated reagents for direct functionalization by converting methionine to the corresponding sulfimide conjugation product.

  化学选择性共轭是通过氧化还原反应的反应性，将N-转移氧化剂与硫醚底物在水环境中进行氧化还原反应，形成共轭产物。在实施例中，利用氧化还原活化的化学标记（ReACT）策略对基于蛋氨酸的蛋白质进行功能化。氧杂环丙烷（Ox）化合物作为氧化剂介导试剂，通过将蛋氨酸转化为相应的磺酰亚胺共轭产物，实现直接功能化。